References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCurrent review of the SarQoL®: a health-related quality of life questionnaire specific to sarcopenia
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Geerinck, Anton ULg et al

in Expert Reviews of Pharmacoeconomics & Outcomes Research (2017), (On line),

INTRODUCTION: Sarcopenia, defined by a progressive and generalized loss of muscle mass and muscle function, is associated with many harmful clinical consequences. Several studies have reported the impact ... [more ▼]

INTRODUCTION: Sarcopenia, defined by a progressive and generalized loss of muscle mass and muscle function, is associated with many harmful clinical consequences. Several studies have reported the impact of sarcopenia on health-related quality of life (HRQoL) using generic quality of life (QoL) questionnaires. The results of these observational studies are quite heterogenous. Indeed, generic tools may not be able to detect subtle effects of sarcopenia on QoL. Recently, a sarcopenia-specific HRQoL questionnaire was developed and validated in a population of sarcopenic subjects to more accurately assess the impact of sarcopenia on QoL. Areas covered: The purpose of this review is to present evidence regarding the impact of sarcopenia on QoL and to introduce a new specific HRQoL questionnaire, the SarQoL®. Expert commentary: The self-administered SarQoL®, initially developed in French, comprises 55 items translated into 22 questions. The questionnaire has been shown to be understandable, valid, consistent, and reliable and can therefore be recommended for clinical and research purposes. The questionnaire is now available in 11 different languages with another 20 translations in progress. The instrument's sensitivity to change still needs to be assessed in future longitudinal studies. [less ▲]

Full Text
Peer Reviewed
See detailHow clinical practitioners assess frailty in their daily practice: an international survey
Bruyère, Olivier ULg; Buckinx, Fanny ULg; Beaudart, Charlotte ULg et al

in Aging Clinical and Experimental Research (2017), (On line),

NTRODUCTION: Various operational definitions have been proposed to assess the frailty condition among older individuals. Our objective was to assess how practitioners measure the geriatric syndrome of ... [more ▼]

NTRODUCTION: Various operational definitions have been proposed to assess the frailty condition among older individuals. Our objective was to assess how practitioners measure the geriatric syndrome of frailty in their daily routine. METHODS: An online survey was sent to national geriatric societies affiliated to the European Union Geriatric Medicine Society (EUGMS) and to members of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). RESULTS: A total of 388 clinicians from 44 countries answered to the survey. Most of them were medical doctors (93%), and their primary field of practice was geriatrics (83%). Two hundred and five clinicians (52.8%) always assessed frailty in their daily practice, 38.1% reported to "sometimes" measure it, and 9.1% never assess it. A substantial proportion of clinicians (64.9%) diagnose frailty using more than one instrument. The most widely used tool was the gait speed test, adopted by 43.8% of the clinicians, followed by clinical frailty scale (34.3%), the SPPB test (30.2%), the frailty phenotype (26.8%) and the frailty index (16.8%). CONCLUSION: A variety of tools is used to assess frailty of older patients in clinical practice highlighting the need for standardisation and guidelines. [less ▲]

Full Text
Peer Reviewed
See detailVitamin D and osteosarcopenia: an update from epidemiological studies.
Bruyère, Olivier ULg; CAVALIER, Etienne ULg; Reginster, Jean-Yves ULg

in Current Opinion in Clinical Nutrition & Metabolic Care (2017), 20

PURPOSE OF REVIEW: The review summarizes recent epidemiological studies that examined the relationship between osteoporosis and sarcopenia to assess the impact of vitamin D status or supplementation on ... [more ▼]

PURPOSE OF REVIEW: The review summarizes recent epidemiological studies that examined the relationship between osteoporosis and sarcopenia to assess the impact of vitamin D status or supplementation on health outcomes related to these two medical conditions. [less ▲]

Full Text
Peer Reviewed
See detailEffects of protein, essential amino acids, B-Hydroxy B-Methylbutyrate, creatine, Dehydroepiandrosterone and fatty acid supplementation on muscle mass, muscle strength and physical performance in older people aged 60 years and over. A systematic review of the litterature.
Beaudart, Charlotte ULg; Rabenda, Véronique ULg; Simmons, Michael et al

in Journal of Nutrition, Health & Aging (2017), (Online First),

Abstract: Objectives: The objective of this study was to perform a systematic review to investigate the effects protein, essential amino acids (EAA), β-hydroxy β-methylbutyrate (HMB), creatine ... [more ▼]

Abstract: Objectives: The objective of this study was to perform a systematic review to investigate the effects protein, essential amino acids (EAA), β-hydroxy β-methylbutyrate (HMB), creatine, dehydroepiandrosterone (DHEA) and fatty acid supplementation on muscle mass, muscle strength and physical performance of elderly subjects. Methods: Using the electronic databases MEDLINE and EMBASE we identified RCTs published until February 2016 which assessed the effects of these nutrient supplementation on muscle strength, muscle mass or physical performance. Study selection and data extraction were performed by two independent reviewers. Results: Search strategy allowed us to identify 23 RCTs. Among them, four used proteins as nutritional supplement, seven EAAs, six creatine, four DHEA and finally, two HMB. From our systematic review, it seems that the effects of these supplementations on muscle health are rather limited. Only consistent effects of EAA supplementation on physical performance (3 out of the 4 RCTs using EAA supplementation found significant effect of this supplementation on physical performance) and HMB supplementation on muscle mass (all the 2 identified RCTs using HMB supplementation found significant effect of this supplementation on muscle mass) have been found across studies. No consistent effects were found for the other types of dietary supplementation. Because of the important limitations in study design, inconsistency and lack of directness, the overall quality of the evidence was judged to be low or very low using the GRADE system. Conclusion: This systematic review showed a limited effect of nutritional supplementation on muscle mass, muscle power and physical function. Inconsistent positive effects were observed for some specific supplementations but the results only concerned one aspect of the muscle. Well designed and appropriately powered RCTs are needed to provide evidence for appropriate clinical recommendations. [less ▲]

Full Text
Peer Reviewed
See detailSkeletal health in breast cancer survivors
Bruyère, Olivier ULg; Bergmann, Pierre; CAVALIER, Etienne ULg et al

in Maturitas (2017), (In press),

Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sectional studies have reported, nevertheless, that patients with breast cancer have a lower bone mass and ... [more ▼]

Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sectional studies have reported, nevertheless, that patients with breast cancer have a lower bone mass and potentially a higher incidence of fractures than expected. In any case, it appears that patients with breast cancer are not protected from osteoporosis, which provides further support for the recommendation that bone health is assessed after a diagnosis of breast cancer. Most adjuvant therapies will lead to increased bone loss and a higher fracture rate. Among the adjuvant therapy options for premenopausal patients with breast cancer, endocrine therapy (ovarian suppression) and chemotherapy can result in cancer treatment-induced bone loss (CTIBL) of up to 10% at the lumbar spine after one year. Antiresorptive therapies prevent CTIBL in premenopausal women with breast cancer. Most of the evidence demonstrating the efficacy of bisphosphonates in the prevention of CTIBL is derived from clinical trials with zoledronic acid. The addition of zoledronic acid 4 mg per six months to adjuvant endocrine therapy maintained and even increased bone mass during a 3-year treatment period and significantly improved disease-free survival in a population of young women who underwent menopause due to the adjuvant treatment. The major contributor to bone loss in the adjuvant treatment of breast cancer in postmenopausal women is the use of aromatase inhibitors (AIs). Oncology trials have underestimated the fracture risk in the setting of AI-induced bone loss. In the ABCSG-18 study, the only trial in which fracture incidence was the primary endpoint, the rate of clinical fractures was close to 10% after 3 years in the placebo group on AIs only. Bisphosphonates and denosumab at osteoporosis treatment doses can counteract AI-induced bone loss. In the ABCSG-18 trial, treatment with denosumab 60 mg injection every 6 months reduced the risk of first clinical fracture relative to placebo by 50%. Current guidelines recommend antiresorptive therapy in patients with a baseline T score of<−2.0 or with two or more clinical risk factors for fracture. These recent guidelines will need to be updated, as similar significant protective effects were seen in women with either normal or low bone mass. Moreover, a formal meta-analysis of individual patient data from more than 18,000 women in 26 randomized trials of adjuvant zoledronic acid or clodronate treatment for early breast cancer revealed that bisphosphonates significantly reduced the risk of first distant recurrence in bone and the risk of breast cancer mortality, at least in postmenopausal women. Even though the increased risk of fracture during adjuvant treatment for breast cancer in postmenopausal women is notable, an enhanced risk of fracture in long-term survivors of breast cancer remains under debate. The most recent studies suggest that Caucasian breast cancer survivors do not have a significantly increased risk of osteoporotic fracture over the long term. [less ▲]

Full Text
Peer Reviewed
See detailPrevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the SENIOR cohort
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; BRUNOIS, Théo ULg et al

in Journal of Musculoskeletal & Neuronal Interactions (2017), 17(3), 209-17

Objective: To investigate the relationship between frailty and sarcopenia, by evaluating the prevalence of sarcopenia among frail, pre-frail and robust elderly nursing home residents in Belgium. Methods ... [more ▼]

Objective: To investigate the relationship between frailty and sarcopenia, by evaluating the prevalence of sarcopenia among frail, pre-frail and robust elderly nursing home residents in Belgium. Methods: This is an analysis of baseline data collected from the SENIOR (Sample of Elderly Nursing home Individuals: an Observational Research) cohort. All subjects received a sarcopenia evaluation, based on the definition proposed by the European Working Group on Sarcopenia in Older People (EWGSOP). The frailty evaluation was primarily based on FRIED’s definition but also on 9 other operational definitions. Results: A total of 662 subjects (73.1% of women) were included in this analysis (mean age: 83.2±8.99 years). The prevalence of sarcopenia was 38.1% whereas the prevalence of frail and pre-frail persons was respectively 24.7% and 61.4%. Among frail, pre-frail and robust subjects, respectively 47%, 38.9% and 16.3% were diagnosed sarcopenic. The prevalence of sarcopenia according to ten different operational definitions of frailty ranged between 32.8 % (i.e. Frail scale Status and Frailty Index) and 47% (i.e. Fried definition). Conclusion: This research highlights that over a third of nursing home residents are sarcopenic and the percentage is almost 50% among frail subjects; those latter constitute about 1 in 4 of the population of nursing home residents studied here. [less ▲]

Full Text
Peer Reviewed
See detailEffects of a giant exercising board game intervention on ambulatory physical activity among nursing home residents: a preliminary study
Mouton, Alexandre ULg; Gillet, Nicolas; Mouton, Flore et al

in Osteoporosis International (2017), 28(S1), 318

Detailed reference viewed: 41 (3 ULg)
Full Text
Peer Reviewed
See detailSurvey of ESCEO algorithm: methodology and results
Bruyère, Olivier ULg

in Osteoporosis International (2017), 28(S1), 635

Detailed reference viewed: 23 (0 ULg)
Full Text
Peer Reviewed
See detailConnected devices in musculo-skeletal health
Bruyère, Olivier ULg

in Osteoporosis International (2017), 28(S1), 88

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailRole of nutrition and physical exercise in maintaining intrinsic capacity
Bruyère, Olivier ULg

in Osteoporosis International (2017), 28(S1), 84

Detailed reference viewed: 36 (0 ULg)
Full Text
Peer Reviewed
See detailValidation of the SarQoL, a specific health-related quality of life questionnaire for Sarcopenia
Beaudart, Charlotte ULg; Biver, Emmanuel; Reginster, Jean-Yves et al

in Journal of cachexia, sarcopenia and muscle (2017), 8(2), 238-44

Background A specific self-administrated health-related quality of life questionnaire for sarcopenia, the Sarcopenia and Quality Of Life (SarQoL®), has been recently developed. This questionnaire is ... [more ▼]

Background A specific self-administrated health-related quality of life questionnaire for sarcopenia, the Sarcopenia and Quality Of Life (SarQoL®), has been recently developed. This questionnaire is composed of 55 items translated into 22 questions and organized into seven domains of quality of life. The objective of the present work is to evaluate the psychometric properties (discriminative power, validity, reliability, floor and ceiling effects) of the SarQoL® questionnaire. Methods Sarcopenic subjects were recruited in an outpatient clinic in Liège, Belgium and were diagnosed according to the algorithm developed by the European Working Group on Sarcopenia in Older People. We compared the score of the SarQoL® between sarcopenic and non-sarcopenic subjects using a logistic regression after adjustment for potential confounding variables. Internal consistency reliability was determined using Cronbach’s alpha coefficient; construct validity was assessed using convergent and divergent validities. Test–retest reliability was verified after a two-week interval using the intra-class correlation coefficient (ICC). At last, floor and ceiling effects were also tested. Results A total of 296 subjects with a median age of 73.3 (68.9–78.6) years were recruited for this study. Among them, 43 were diagnosed sarcopenic. After adjustment for potential confounding factors, the total score and the scores of the different dimensions of the SarQoL® questionnaire were significantly lower for sarcopenic than for non-sarcopenic subjects (54.7 (45.9– 66.3) for sarcopenic vs. 67.8 (57.3 – 79.0) for non sarcopenic, OR 0.93 (95%CI 0.90–0.96)). Regarding internal consistency, the Cronbach’s alpha coefficient was 0.87. The SarQoL® questionnaire data showed good correlation with some domains of the Short-Form 36 (SF-36) and the EuroQoL 5-dimension (EQ-5D) questionnaires and with the mobility test. An excellent agreement between the test and the retest was found with an ICC of 0.91 (95% CI 0.82–0.95). At last, neither floor nor ceiling effects were detected. Conclusions The SarQoL® questionnaire is valid, consistent, and reliable and can therefore be recommended for clinical and research purposes. However, its sensitivity to change needs to be assessed in future longitudinal studies. [less ▲]

Detailed reference viewed: 33 (6 ULg)
Full Text
Peer Reviewed
See detailHealth outcomes of sarcopenia: a systematic review and metaanalysis.
Beaudart, Charlotte ULg; Zaaria, M.; Pasleau, Françoise ULg et al

in Osteoporosis International (2017), 28 Suppl 1

Detailed reference viewed: 32 (3 ULg)
Full Text
Peer Reviewed
See detailResults of the SarcoPhAge study after 2 years of follow-up.
Beaudart, Charlotte ULg; Locquet, Médéa ULg; Reginster, Jean-Yves ULg et al

in Journal of Frailty & Aging (2017), 6 Suppl 1

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailHealth outcomes of sarcopenia: a systematic review and meta-analysis.
Zaaria, M.; Pasleau, Françoise ULg; Reginster, Jean-Yves ULg et al

in Journal of Frailty & Aging (2017), 6 Suppl 1

Detailed reference viewed: 27 (2 ULg)
Full Text
Peer Reviewed
See detailL'étude SarcoPhAge: devenir des sujets sarcopéniques après 2 ans de suivi.
Beaudart, Charlotte ULg; Locquet, Médéa ULg; Reginster, Jean-Yves ULg et al

in L'Année Gérontologique (2017), 31(1), 42

Detailed reference viewed: 24 (2 ULg)
Full Text
Peer Reviewed
See detailAnalyse des conséquences cliniques de la sarcopénie: une revue systématique et méta-analyse.
Beaudart, Charlotte ULg; Zaaria, M.; Pasleau, F. et al

in L'année Gérontologique (2017), 31(1), 18

Detailed reference viewed: 38 (6 ULg)